[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 6
2003 4
2004 12
2005 19
2006 15
2007 20
2008 14
2009 11
2010 14
2011 15
2012 28
2013 39
2014 20
2015 25
2016 29
2017 17
2018 23
2019 15
2020 19
2021 38
2022 32
2023 15
2024 17
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N; PIONEER 10 Investigators. Yabe D, et al. Among authors: kaneto h. Lancet Diabetes Endocrinol. 2020 May;8(5):392-406. doi: 10.1016/S2213-8587(20)30074-7. Lancet Diabetes Endocrinol. 2020. PMID: 32333876 Clinical Trial.
Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Kimura T, Katakura Y, Shimoda M, Kawasaki F, Yamabe M, Tatsumi F, Matsuki M, Iwamoto Y, Anno T, Fushimi Y, Kamei S, Kimura Y, Nakanishi S, Mune T, Kaku K, Kaneto H; COMING study Group. Kimura T, et al. Among authors: kaneto h. Diabetes Obes Metab. 2023 Dec;25(12):3632-3647. doi: 10.1111/dom.15258. Epub 2023 Aug 30. Diabetes Obes Metab. 2023. PMID: 37646192 Clinical Trial.
Large adrenal ganglioneuroma.
Sasaki S, Yasuda T, Kaneto H, Otsuki M, Tabuchi Y, Fujita Y, Kubo F, Tsuji M, Fujisawa K, Kasami R, Kitamura T, Miyatsuka T, Katakami N, Kawamori D, Matsuoka TA, Imagawa A, Shimomura I. Sasaki S, et al. Among authors: kaneto h. Intern Med. 2012;51(17):2365-70. doi: 10.2169/internalmedicine.51.7726. Epub 2012 Sep 1. Intern Med. 2012. PMID: 22975550 Free article.
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Kurozumi A, Hatazaki M, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Kato K, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: kaneto h. Cardiovasc Diabetol. 2023 Jun 22;22(1):143. doi: 10.1186/s12933-023-01879-4. Cardiovasc Diabetol. 2023. PMID: 37349722 Free PMC article. Clinical Trial.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Shimoda M, Yamasaki Y, Nogami Y, Shirakiya Y, Nakanishi S, Mune T, Kaku K, Kaneto H. Iwamoto Y, et al. Among authors: kaneto h. Diabetes Obes Metab. 2024 Dec;26(12):5982-5994. doi: 10.1111/dom.15972. Epub 2024 Sep 30. Diabetes Obes Metab. 2024. PMID: 39344853
Obesity and Dyslipidemia Synergistically Exacerbate Psoriatic Skin Inflammation.
Ikeda K, Morizane S, Akagi T, Hiramatsu-Asano S, Tachibana K, Yahagi A, Iseki M, Kaneto H, Wada J, Ishihara K, Morita Y, Mukai T. Ikeda K, et al. Among authors: kaneto h. Int J Mol Sci. 2022 Apr 13;23(8):4312. doi: 10.3390/ijms23084312. Int J Mol Sci. 2022. PMID: 35457132 Free PMC article.
Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Shimoda M, Nogami Y, Shirakiya Y, Nakanishi S, Mune T, Kaku K, Kaneto H. Iwamoto Y, et al. Among authors: kaneto h. Diabetes Obes Metab. 2024 Jun;26(6):2339-2348. doi: 10.1111/dom.15548. Epub 2024 Mar 19. Diabetes Obes Metab. 2024. PMID: 38504118
Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
Kimura T, Kubo M, Takahashi K, Wamata R, Iwamoto Y, Iwamoto H, Katakura Y, Sanada J, Fushimi Y, Shimoda M, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H. Kimura T, et al. Among authors: kaneto h. J Diabetes Res. 2024 Jan 4;2024:5880589. doi: 10.1155/2024/5880589. eCollection 2024. J Diabetes Res. 2024. PMID: 38223524 Free PMC article.
386 results